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Abstract
Background: Angiotensin converting enzyme inhibitors are routinely prescribed to patients with
chronic kidney disease because of their known renoprotective effects. We evaluated the effect of
short-term therapy with the angiotensin converting enzyme inhibitor, enalapril, in early Alport
syndrome, defined as disease duration less than 10 years and a normal glomerular filtration rate.
Methods: 11 children with early Alport syndrome were investigated. Two consecutive early
morning urine specimens were collected at the start of the study for measurement of urinary
creatinine, total protein, albumin, TGF-β , and nitrite excretion. Patients were treated with
enalapril, ≅  0.2 mg/kg/day, once a day for 14 days. Two early morning urine specimens were
collected on days 13 and 14 of enalapril treatment and two weeks later for measurement of urinary
creatinine, total protein, albumin, TGF-β , and nitrite excretion.
Results: Prior to treatment, urinary excretion of transforming growth factor-β  and nitrite, the
major metabolite of nitric oxide, was within normal limits in all patients. Administration of enalapril
for 2 weeks did not alter urinary albumin, transforming growth factor-β , or nitrite excretion.
Conclusion: These findings suggest that early Alport syndrome represents a disease involving
exclusively intrinsic glomerular barrier dysfunction. At this stage of the illness, there is no evidence
of angiotensin II-mediated proteinuria or increased production of transforming growth factor-β
and, therefore, routine treatment with an angiotensin converting enzyme inhibitor may not be
warranted.
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Background
Alport syndrome (AS) is a glomerulopathy caused by ge-
netic mutations in type IV collagen, the main collagenous
constituent of the glomerular basement membrane
(GBM) [1]. The predominant form of AS is inherited as an
X-linked dominant disease. Hematuria is the initial find-
ing and proteinuria develops later secondary to the defec-
tive composition and ultrastructure of the GBM [1].
Proteinuria increases with age and is a useful marker of
disease progression. End stage renal disease (ESRD) even-
tually ensues in affected males, while the disease course is
more benign in females. There is no specific therapy for AS
and renal transplantation remains the definitive treat-
ment [1].
Transforming growth factor-β  (TGF-β ) and nitric oxide
(NO) are important mediators of renal disease progres-
sion. TGF-β  is a fibrogenic cytokine involved in normal
wound healing and pathological fibrosis (). Intra-renal
production of TGF-β  is enhanced in patients with IgA ne-
phropathy, diabetic nephropathy, lupus nephritis, and fo-
cal segmental glomerulosclerosis (FSGS) when they
develop glomerular scarring [3]. The factors that control
TGF-β  overexpression in these renal diseases are not well
understood. NO is a short-acting signaling molecule that
is involved in the regulation of glomerular hemodynam-
ics, mesangial proliferation, and net mesangial matrix
production [4]. Diminished renal production in chronic
renal disease may contribute to kidney fibrosis [5]. The
role of TGF-β  and NO in promoting progressive disease in
AS is not known.
Treatment with angiotensin converting enzyme inhibitors
(ACEI) is renoprotective in virtually all proteinuric forms
of kidney disease [6]. By reducing intraglomerular hyper-
tension, ACEI prevent glomerular hyperfiltration. Howev-
er, because angiotensin II is a potent inducer of TGF-β
release, ACEI may also diminish renal fibrosis by a non-
hemodynamic mechanism [7,8]. Both ACEI and NO re-
tard the progression to kidney failure and their renopro-
tective effects correlate with suppression of TGF-β  [9–12].
In view of these observations, we performed the following
study to determine urinary protein, TGF-β , and nitrite (the
stable metabolite of NO) excretion in children with early




11 children (5M:6F), mean age 8.6 ± 1.1 years, with renal
early biopsy-proven AS were included in this study. The
duration of disease from the date of diagnostic biopsy un-
til participation in this study was 56 ± 12 months. The es-
timated glomerular filtration rate (GFR) was calculated
using the age and sex-appropriate length-serum creatinine
formulas [13,14]. Normal levels of blood pressure were
defined based upon the updated Task Force Report on
Blood Pressure Control in Children and Adolescents [15].
Clinical protocol:
Two consecutive early morning urine specimens were col-
lected at the start of the study for measurement of urinary
creatinine, albumin, TGF-β , and nitrite excretion. Patients
were then given enalapril (EN), ≅  0.2 mg/kg/day, once a
day for 14 days. The daily dose of enalapril was between
5–10 mg. The amount of drug and duration of treatment
were the same as in a previous evaluation of ACEI therapy
in sickle cell nephropathy [16]. Two early morning urine
specimens were collected on days 13 and 14 of EN treat-
ment. Administration of the ACEI was then stopped and
two early morning urine specimens were collected again
two weeks later. This study was approved by the Institu-
tional Review Board of the Schneider Children's Hospital
of the North Shore-Long Island Jewish Health System and
informed consent was signed prior to patient enrollment.
Analytical methods:
Urine creatinine was measured using standard methods.
Urinary albumin and TGF-β  were determined using com-
mercially available EIA kits (R & D Systems, Minneapolis,
MN). Urinary albumin excretion was expressed as the
urine albumin: creatinine ratio (UAC) (mg/mg). The Gre-
iss reaction was used to measure urinary nitrite excretion,
which was expressed as nmol/mg creatinine.
Statistical analysis:
Data are presented as mean ± SE. Differences between
groups were analyzed using the ANOVA and t-test and re-
sults were considered significant if P < 0.05.
Results
In the 11 patients who enrolled in this clinical study, the
estimated GFR was 146 ± 14 ml/min/1.73 m2 . Blood was
not drawn at the end of the 14-day EN treatment period
and, as a consequence, the effect of ACEl therapy on GFR
could not be determined. All of the children had a normal
blood pressure without antihypertensive medications.
Prior to EN treatment, the mean UAC was 1.2 ± 0.9
(range: 0.01–9.6). In addition, the level of TGF-β  in the
urine was 60 ± 11 pg/mg creatinine, within the range ob-
served in healthy subjects (50–300 pg/mg creatinine)
[17]. Finally, the baseline urinary nitrite excretion was
1466 ± 330 versus 836 ± 274 nmol/mg creatinine in nor-
mal control children (P = 0.16).
At the end of two weeks of EN therapy, UAC was 130 ±
33% of pre-treatment levels, and remained elevated 14
days after treatment was discontinued, namely 134 ± 31%
of the baseline value. A decline in UAC >33% was ob-BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/2
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served in only 2 patients, both of whose initial urine albu-
min concentration was >1000 mg/L (the urinary albumin:
creatinine ratio (mg/mg) was 1.4 and 9.6 in these 2 chil-
dren). In the urine samples collected after two weeks of
ACEl therapy and after withdrawing EN two weeks later,
the urinary TGF-β  excretion was 55 ± 11 and 57 ± 10 pg/
mg creatinine, respectively. Compared to pre-treatment
levels, urinary TGF-β  levels were 110 ± 23 and 112 ± 30%,
respectively, of the baseline value at the completion of the
2-week course of ACEI therapy and 2 weeks after discon-
tinuation of the medication (P > 0.4). Similarly, short-
term ACEI therapy had no effect on urinary nitrite excre-
tion, 92 ± 20 and 84 ± 7% of baseline level, after 2 wk of
EN therapy, and 2 wk after discontinuing the ACEI, re-
spectively (P > 0.3). The changes in urinary TGF-β  and ni-
trite excretion were not different in the two patients with
significant albuminuria compared to the other 9 children.
All of the urinary measurements, i.e., albuminuria, TGF-β ,
and nitrite excretion, were comparable in boys and girls at
baseline and in response to ACEI therapy. Although there
was no correlation between the effect of EN therapy on al-
buminuria and the change in urinary TGF-β  or nitrite ex-
cretion, the later two variables were significantly related to
one another (P < 0.04).
Discussion
The children with biopsy-proven AS who were enrolled in
this study had early disease, based upon a normal GFR,
normal blood pressure, and sub-nephrotic range pro-
teinuria. The urinary abnormalities observed in these pa-
tients were probably a consequence of genetic mutations
in the α 5 chains of type IV collagen and defective GBM ul-
trastructure [1]. Although the long-term risk of disease
progression differs in male versus female patients, based
on the similar level of urinary protein excretion, it is likely
that at the time of these investigations glomerular barrier
function and the mediators of proteinuria were similar in
all of the study participants.
In other progressive glomerulopathies, alterations in TGF-
β  and NO have been implicated in the steady decline in re-
nal function, glomerulosclerosis, and tubulointerstitial fi-
brosis. The source of the fibrogenic cytokines and
vasoactive mediators varies in different disease entities.
For example, in IgA nephropathy, immune complex ne-
phritis, and FSGS increased intra-renal levels of TGF-β  and
NO are the consequence of release by resident and/or in-
filtrating immunoeffector cells [3]. In contrast, in diabetic
nephropathy, metabolic disturbances, namely hyperglyc-
emia, directly modulate TGF-β  and NO synthesis by
glomerular mesangial and renal tubular epithelial cells
[3,7]. In diabetic nephropathy, alterations in intra-renal
TGF-β  production have been assessed by measuring uri-
nary excretion of this cytokine [17].
Measurements of urinary nitrite excretion are less inter-
pretable than determinations of urinary nitrite + nitrate
excretion because a variable portion (50–90%) of NO-re-
lated end products in the urine may represent nitrate [18].
However, nitrate excretion is primarily dependent on die-
tary intake and there is a close correlation between urinary
nitrite and nitrate excretion in healthy subjects [18].
Therefore, because this was a short-term study and pa-
tients did not modify their diet for the duration of the 4-
week experimental period, it is likely that the urinary ni-
trite excretion accurately reflects renal NO synthesis. The
small non-significant decrease in urinary nitrite excretion
after ACEI therapy, despite the known effect of these drugs
to stimulate endothelial NO release, may be the conse-
quence of a decline in GFR. A blood sample was not ob-
tained at the conclusion of ACEI treatment to enable
measurement of renal function. However, most pediatric
patients with a GFR in the range noted for the children in
this study do not develop a decline in renal function in re-
sponse to EN therapy.
Our data indicate that in early AS, hematuria and sub-ne-
phrotic range proteinuria are exclusively the result of in-
trinsic glomerular barrier dysfunction and are not the
consequence of acutely reversible alterations in glomeru-
lar hemodynamics. In contrast to children with type I di-
abetes mellitus [17], there is no increase in renal TGF-β  or
NO production at this stage of the disease. The clinical
data are in agreement with recent findings in a transgenic
model of autosomal recessive Alport syndrome in which
TGF-β  was only involved in the late progression of the ne-
phropathy [19,20]. Although male patients with AS are at
greater risk than females of developing progressive kidney
failure, our findings suggest that differences in renal pro-
duction of TGF-β  in the early phase of the disease cannot
explain the impact of gender on prognosis. Although
higher levels of proteinuria may stimulate release of these
and other inflammatory mediators, this pathogenetic
mechanism is not activated in early AS.
In virtually all forms of glomerular disease, administra-
tion of ACEl to patients with nephrotic range proteinuria
results in a significant and reproducible reduction in uri-
nary protein excretion and presumably an improvement
in the long-term prognosis [6]. However, early in the
course of AS, when our patients had sub-nephrotic range
proteinuria there was no evidence of an angiotensin II-
sensitive alteration in glomerular hemodynamics that
manifested as a decrease in albuminuria. The more pro-
nounced antiproteinuric response in the 2 children whose
initial urine albumin concentration exceeded 1000 mg/L
is consistent with a previous report of enalapril use in
pediatric patients with AS [21].BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/2
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It is important to note that our protocol to determine the
effect of short-term administration of ACEl on urinary
protein excretion has been effective in other forms of
glomerular disease in which hemodynamic alterations
have been linked to perturbations in glomerular permse-
lectivity, namely sickle cell nephropathy [16]. We cannot
exclude the possibility that once-a-day administration of
EN was ineffective because of different pharmacokinetics
and a shorter drug half-life in children. The response to
short-term ACEI was significantly lower in our patients
with AS (2/11 children had >33% reduction in albuminu-
ria) versus published reports in adults with sickle cell ne-
phropathy (10/10 had a comparable decrease in
albuminuria) (P < 0.0005) [16]. The 95% confidence in-
terval on this difference indicates that at most 40% of chil-
dren with AS are likely to demonstrate a meaningful
reduction in albuminuria following 2 weeks of EN thera-
py. Thus, despite the small sample size in this study, it is
reasonable to conclude that ACEI treatment will be inef-
fective in lowering urinary protein excretion in children
with early AS.
Whether long-term ACEI therapy is effective in patients
with AS who have developed heavy proteinuria is uncer-
tain. Additional studies will be needed to determine
whether ACEI treatment at later stages of the disease re-
duces proteinuria, precisely when in the disease course
ACEI responsiveness supervenes, and whether this change
is paralleled by alterations in urinary TGF-β  and nitrite ex-
cretion. Experimental protocols designed to evaluate the
impact of ACEI therapy in transgenic models of AS will
help clarify the role of this treatment at various stages in
the course of the disease.
Conclusion
Our results suggest that early AS represents an isolated de-
fect in GBM composition and ultrastructure resulting in a
pure glomerular protein leak. At this stage of the disease,
there is no stimulus to increase TGF-β  or NO production
nor is there evidence of an angiotensin II-sensitive altera-
tion in glomerular hemodynamics. Short-term adminis-
tration of an ACEI to patients with early AS does not cause
a reversible decrease in proteinuria. We speculate that
with longer duration of disease and increasing urinary
protein excretion, the pathophysiology of AS becomes
similar to other glomerulopathies with involvement of al-
tered glomerular hemodynamics, inflammatory media-
tors, chemokines, and fibrogenic cytokines. At this
advanced stage, aggressive ACEI therapy may have a reno-
protective role. Further studies are needed to determine
the exact time point in the course of AS when administra-
tion of an ACEI is a useful intervention to effectively lower
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